A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to generate defence proteins, which are then passed to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Maternal antibodies passed through the placenta safeguard newborns from day one
- Coverage achievable with 2-week gap before early delivery
- Vaccination during third trimester still provides significant infant protection
Compelling evidence from current research
The effectiveness of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study conducted across England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately 90 per cent of all births during that six-month timeframe, providing strong and reliable data of the vaccine’s practical effectiveness. The study’s conclusions have been validated by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The breadth of this investigation offers healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This clear distinction emphasises the vaccine’s vital importance in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme introduced in the UK in 2024.
Methodology and scope of study
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The large sample size and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology captured practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to feed and breathe adequately. Parents often witness their babies visibly struggling, their chests heaving as they try to pull enough air into their damaged lungs. Whilst the majority of babies improve through supportive care, a small but significant number die from RSV-related complications each year, making vaccination as prevention a vital health service imperative for defending the youngest and most at-risk individuals in the population.
- RSV causes lung inflammation, leading to serious respiratory problems in infants
- Half of all newborns contract the virus during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- Small numbers of infants die from RSV complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have stressed the importance of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The messaging from health authorities stays clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has provided reassurance to pregnant women that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These regional differences demonstrate variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics demonstrates consistently strong protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to engage with women during pregnancy
- Geographic variations in vaccine uptake rates across England require targeted improvement
- Community health services adapting programmes to align with local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness translates into concrete gains for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the launch of this preventative solution, the 80% reduction in admissions represents thousands of infants protected against critical disease. Parents no longer face the upsetting situation of seeing their babies labour to breathe or difficulty feeding, symptoms that define critical RSV illness. The vaccine has substantially transformed the terrain of neonatal lung health, providing expectant mothers a proactive tool to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection caused devastating brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s advocacy for the jab highlights the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to women in pregnancy in their third trimester, changing what was once an unavoidable seasonal threat into a controllable health concern.